<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>oncology</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>oncology | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Use of tryptic peptide MALDI mass spectrometry imaging to identify the spatial proteomic landscape of colorectal cancer liver metastases.
Authors: Li, C. M. Y.; Briggs, M.; Lee, Y. R.; Tin, T.; Young, C.; Pierides, J.; Kaur, G.; Drew, P.; Maddern, G.; Hoffman, P.; Klinger-Hoffman, M.; Fenix, K.
Score: 1.0, Published: 2024-01-25 DOI: 10.1101/2024.01.24.24301748
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. CRC liver metastases (CRLM) are often resistant to conventional treatments, with high rates of recurrence.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/oncology/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="oncology" />
<meta property="og:description" content="Use of tryptic peptide MALDI mass spectrometry imaging to identify the spatial proteomic landscape of colorectal cancer liver metastases.
Authors: Li, C. M. Y.; Briggs, M.; Lee, Y. R.; Tin, T.; Young, C.; Pierides, J.; Kaur, G.; Drew, P.; Maddern, G.; Hoffman, P.; Klinger-Hoffman, M.; Fenix, K.
Score: 1.0, Published: 2024-01-25 DOI: 10.1101/2024.01.24.24301748
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. CRC liver metastases (CRLM) are often resistant to conventional treatments, with high rates of recurrence." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/oncology/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2024-01-28T10:37:59+00:00" />
<meta property="article:modified_time" content="2024-01-28T10:37:59+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="oncology"/>
<meta name="twitter:description" content="Use of tryptic peptide MALDI mass spectrometry imaging to identify the spatial proteomic landscape of colorectal cancer liver metastases.
Authors: Li, C. M. Y.; Briggs, M.; Lee, Y. R.; Tin, T.; Young, C.; Pierides, J.; Kaur, G.; Drew, P.; Maddern, G.; Hoffman, P.; Klinger-Hoffman, M.; Fenix, K.
Score: 1.0, Published: 2024-01-25 DOI: 10.1101/2024.01.24.24301748
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. CRC liver metastases (CRLM) are often resistant to conventional treatments, with high rates of recurrence."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "oncology",
      "item": "https://trxiv.yorks0n.com/posts/oncology/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "oncology",
  "name": "oncology",
  "description": "Use of tryptic peptide MALDI mass spectrometry imaging to identify the spatial proteomic landscape of colorectal cancer liver metastases.\nAuthors: Li, C. M. Y.; Briggs, M.; Lee, Y. R.; Tin, T.; Young, C.; Pierides, J.; Kaur, G.; Drew, P.; Maddern, G.; Hoffman, P.; Klinger-Hoffman, M.; Fenix, K.\nScore: 1.0, Published: 2024-01-25 DOI: 10.1101/2024.01.24.24301748\nColorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. CRC liver metastases (CRLM) are often resistant to conventional treatments, with high rates of recurrence.",
  "keywords": [
    
  ],
  "articleBody": " Use of tryptic peptide MALDI mass spectrometry imaging to identify the spatial proteomic landscape of colorectal cancer liver metastases.\nAuthors: Li, C. M. Y.; Briggs, M.; Lee, Y. R.; Tin, T.; Young, C.; Pierides, J.; Kaur, G.; Drew, P.; Maddern, G.; Hoffman, P.; Klinger-Hoffman, M.; Fenix, K.\nScore: 1.0, Published: 2024-01-25 DOI: 10.1101/2024.01.24.24301748\nColorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. CRC liver metastases (CRLM) are often resistant to conventional treatments, with high rates of recurrence. Therefore, it is crucial to identify biomarkers for CRLM patients that predict cancer progression. This study utilised matrix-assisted laser desorption/ionisation mass spectrometry imaging (MALDI-MSI) in combination with liquid chromatography-tandem mass spectrometry (LC-MS/MS) to spatially map the CRLM tumour proteome. CRLM tissue microarrays (TMAs) of 84 patients were analysed using tryptic peptide MALDI-MSI to spatially monitor peptide abundances across CRLM tissues. Abundance of peptides was compared between tumour vs stroma, male vs female and across three groups of patients based on overall survival (0-3 years, 4-6 years, and 7+ years). Peptides were then characterised and matched using LC-MS/MS. A total of 471 potential peptides were identified by MALDI-MSI. Our results show that two unidentified m/z values (1589.876 and 1092.727) had significantly higher intensities in tumours compared to stroma. Ten m/z values were identified to have correlation with biological sex. Survival analysis identified three peptides (Histone H4, Hemoglobin subunit alpha, and Inosine-5-monophosphate dehydrogenase 2) and two unidentified m/z values (1305.840 and 1661.060) that were significantly higher in patients with shorter survival (0-3 years relative to 4-6 years and 7+ years). This is the first study using MALDI-MSI, combined with LC-MS/MS, on a large cohort of CRLM patients to identify the spatial proteome in this malignancy. Further, we identify several protein candidates that may be suitable for drug targeting or for future prognostic biomarker development.\nMulti-omics profiling with untargeted proteomics for blood-based early detection of lung cancer\nAuthors: Koh, B.; Liu, M.; Almonte, R.; Ariad, D.; Bundalian, G.; Chan, J.; Choi, J.; Chou, W.-F.; Cuaresma, R.; Hoedt, E.; Hopper, L.; Hu, Y.; Jain, A.; Khaledian, E.; Khin, T.; Kokate, A.; Lee, J.-Y.; Leung, S.; Lin, C.-H.; Marispini, M.; Malekpour, H.; Mora, M.; Mudaliar, N.; Nouri Golmaei, S.; Ramaiah, M.; Ramaswamy, S.; Ranjan, P.; Shu, G.; Spiro, P.; Ta, B.; Vitko, D.; Waiss, J.; Yanagihara, Z.; Zawada, R.; Zeng, J. Y.; Zhang, S.; Yee, J.; Blume, J. E.; Belthangady, C.; Wilcox, B.; Ma, P.\nScore: 30.5, Published: 2024-01-04 DOI: 10.1101/2024.01.03.24300798\nBlood-based approaches to detect early-stage cancer provide an opportunity to improve survival rates for lung cancer, the most lethal cancer world-wide. Multiple approaches for blood-based cancer detection using molecular analytes derived from individual omics (cell-free DNA, RNA transcripts, proteins, metabolites) have been developed and tested, generally showing significantly lower sensitivity for early-stage versus late-stage cancer. We hypothesized that an approach using multiple types of molecular analytes, including broad and untargeted coverage of proteins, could identify biomarkers that more directly reveal changes in gene expression and molecular phenotype in response to carcinogenesis to potentially improve detection of early-stage lung cancer. To that end, we designed and conducted one of the largest multi-omics, observational studies to date, enrolling 2513 case and control subjects. Multi-omics profiling detected 113,671 peptides corresponding to 8385 protein groups, 219,729 RNA transcripts, 71,756 RNA introns, and 1801 metabolites across all subject samples. We then developed a machine learning-based classifier for lung cancer detection comprising 682 of these multi-omics analytes. This multi-omics classifier demonstrated 89%, 80%, and 98-100% sensitivity for all-stage, stage I, and stage III-IV lung cancer, respectively, at 89% specificity in a validation set. The application of a multi-omics platform for discovery of blood-based disease biomarkers, including proteins and complementary molecular analytes, enables the noninvasive detection of early-stage lung cancer with the potential for downstaging at initial diagnosis and the improvement of clinical outcomes.\n",
  "wordCount" : "633",
  "inLanguage": "en",
  "datePublished": "2024-01-28T10:37:59Z",
  "dateModified": "2024-01-28T10:37:59Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/oncology/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      oncology
    </h1>
    <div class="post-meta">&lt;span&gt;updated on January 28, 2024&lt;/span&gt;

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2024.01.24.24301748">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2024.01.24.24301748" aria-expanded="false" aria-controls="flush-collapse10.1101/2024.01.24.24301748">
        <p class="paperTitle">Use of tryptic peptide MALDI mass spectrometry imaging to identify the spatial proteomic landscape of colorectal cancer liver metastases.</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2024.01.24.24301748" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2024.01.24.24301748" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Li, C. M. Y.; Briggs, M.; Lee, Y. R.; Tin, T.; Young, C.; Pierides, J.; Kaur, G.; Drew, P.; Maddern, G.; Hoffman, P.; Klinger-Hoffman, M.; Fenix, K.</p>
        <p class="info">Score: 1.0, Published: 2024-01-25 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2024.01.24.24301748' target='https://doi.org/10.1101/2024.01.24.24301748'> 10.1101/2024.01.24.24301748</a></p>
        <p class="abstract">Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. CRC liver metastases (CRLM) are often resistant to conventional treatments, with high rates of recurrence. Therefore, it is crucial to identify biomarkers for CRLM patients that predict cancer progression. This study utilised matrix-assisted laser desorption/ionisation mass spectrometry imaging (MALDI-MSI) in combination with liquid chromatography-tandem mass spectrometry (LC-MS/MS) to spatially map the CRLM tumour proteome. CRLM tissue microarrays (TMAs) of 84 patients were analysed using tryptic peptide MALDI-MSI to spatially monitor peptide abundances across CRLM tissues. Abundance of peptides was compared between tumour vs stroma, male vs female and across three groups of patients based on overall survival (0-3 years, 4-6 years, and 7&#43; years). Peptides were then characterised and matched using LC-MS/MS. A total of 471 potential peptides were identified by MALDI-MSI. Our results show that two unidentified m/z values (1589.876 and 1092.727) had significantly higher intensities in tumours compared to stroma. Ten m/z values were identified to have correlation with biological sex. Survival analysis identified three peptides (Histone H4, Hemoglobin subunit alpha, and Inosine-5-monophosphate dehydrogenase 2) and two unidentified m/z values (1305.840 and 1661.060) that were significantly higher in patients with shorter survival (0-3 years relative to 4-6 years and 7&#43; years). This is the first study using MALDI-MSI, combined with LC-MS/MS, on a large cohort of CRLM patients to identify the spatial proteome in this malignancy. Further, we identify several protein candidates that may be suitable for drug targeting or for future prognostic biomarker development.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2024.01.03.24300798">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2024.01.03.24300798" aria-expanded="false" aria-controls="flush-collapse10.1101/2024.01.03.24300798">
        <p class="paperTitle">Multi-omics profiling with untargeted proteomics for blood-based early detection of lung cancer</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2024.01.03.24300798" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2024.01.03.24300798" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Koh, B.; Liu, M.; Almonte, R.; Ariad, D.; Bundalian, G.; Chan, J.; Choi, J.; Chou, W.-F.; Cuaresma, R.; Hoedt, E.; Hopper, L.; Hu, Y.; Jain, A.; Khaledian, E.; Khin, T.; Kokate, A.; Lee, J.-Y.; Leung, S.; Lin, C.-H.; Marispini, M.; Malekpour, H.; Mora, M.; Mudaliar, N.; Nouri Golmaei, S.; Ramaiah, M.; Ramaswamy, S.; Ranjan, P.; Shu, G.; Spiro, P.; Ta, B.; Vitko, D.; Waiss, J.; Yanagihara, Z.; Zawada, R.; Zeng, J. Y.; Zhang, S.; Yee, J.; Blume, J. E.; Belthangady, C.; Wilcox, B.; Ma, P.</p>
        <p class="info">Score: 30.5, Published: 2024-01-04 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2024.01.03.24300798' target='https://doi.org/10.1101/2024.01.03.24300798'> 10.1101/2024.01.03.24300798</a></p>
        <p class="abstract">Blood-based approaches to detect early-stage cancer provide an opportunity to improve survival rates for lung cancer, the most lethal cancer world-wide. Multiple approaches for blood-based cancer detection using molecular analytes derived from individual  omics (cell-free DNA, RNA transcripts, proteins, metabolites) have been developed and tested, generally showing significantly lower sensitivity for early-stage versus late-stage cancer. We hypothesized that an approach using multiple types of molecular analytes, including broad and untargeted coverage of proteins, could identify biomarkers that more directly reveal changes in gene expression and molecular phenotype in response to carcinogenesis to potentially improve detection of early-stage lung cancer. To that end, we designed and conducted one of the largest multi-omics, observational studies to date, enrolling 2513 case and control subjects. Multi-omics profiling detected 113,671 peptides corresponding to 8385 protein groups, 219,729 RNA transcripts, 71,756 RNA introns, and 1801 metabolites across all subject samples. We then developed a machine learning-based classifier for lung cancer detection comprising 682 of these multi-omics analytes. This multi-omics classifier demonstrated 89%, 80%, and 98-100% sensitivity for all-stage, stage I, and stage III-IV lung cancer, respectively, at 89% specificity in a validation set. The application of a multi-omics platform for discovery of blood-based disease biomarkers, including proteins and complementary molecular analytes, enables the noninvasive detection of early-stage lung cancer with the potential for downstaging at initial diagnosis and the improvement of clinical outcomes.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2024 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        Â· Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
